|
|
Post by vissertrades on Dec 21, 2015 14:47:13 GMT -5
Sanofi's spot for Afrezza and TS applications. This would explain the "weird" treading water situation as Sanofi know's they are out and Mannkind is mum regarding future. God I hope Google has swooped in along with Dexcom as that would make sense...
|
|
|
|
Post by dreamboatcruise on Dec 21, 2015 14:53:11 GMT -5
Seems like you are proposing an impossible rescue from a seemingly implausible problem.
|
|
|
|
Post by mssciguy on Dec 21, 2015 14:55:30 GMT -5
Sanofi's spot for Afrezza and TS applications. This would explain the "weird" treading water situation as Sanofi know's they are out and Mannkind is mum regarding future. God I hope Google has swooped in along with Dexcom as that would make sense... Of course Sanofi could have turned on the spigot by now, no aggression in their sales approach. Is toujeo really that great? Is aphidra really that great? Are GLP-1s really that great? Where are the clamp study results? Where is the Ph3, EU? Where is the global release? Where is the insurance, where is the pricing parity? |
|
|
|
Post by jay1ajay1a on Dec 21, 2015 16:22:10 GMT -5
We just need to keep waiting and it will all become very clear. Wait that's what I have been doing.
|
|
|
|
Post by bradleysbest on Dec 21, 2015 16:24:43 GMT -5
How could this be when SNY has ability to match any offer. I can only hope other companies are showing interest or putting together offers in the hope SNY gets it act together.
|
|
|
|
Post by suebeeee1 on Dec 21, 2015 17:59:49 GMT -5
How could this be when SNY has ability to match any offer. I can only hope other companies are showing interest or putting together offers in the hope SNY gets it act together. Not so sure that SNY could match an offer from Google. While it would be nice, it is so improbable that it shouldn't even be speculated upon. Only a dream....... |
|
|
|
Post by dudley on Dec 21, 2015 18:33:26 GMT -5
Good grief, this is complete nonsense. Sanofi has spent hundreds of millions of dollars to acquire exclusive rights to distribute Afrezza globally. Per Al Mann they were so eager to have it they started planning before the agreement was even officially signed. Now that real world experience has shown Afrezza to truly be in a class by itself and barely 10 months into what they undoubtedly understood would be a gradual uptake curve "investors" are so desperate they are coming up with nonsense like this?
They just announced the discount card program would continue through 2016. They are in the middle of the pediatric trial. Results from that trial will HAVE to show clear superiority if they simply adjust the dosing period to be 15 minutes after the meal begins. SNY must understand that just as they must understand that a label change to clear superiority opens up the floodgates to demand from all sides - doctors and patients - as well as prime insurance coverage. A medication proven to lower HbA1c, hypos, and all the attendant impacts of diabetes such as neuropathy, blindness, etc. will be unmatched in the treatment universe. A label change allowing these statements both in advertising and sales literature - THAT is what they are "waiting for", almost guaranteed. The rollout and introductions will continue, but the massive blitz will not occur until a label change - it is only common sense and smart business.
Sanofi is most certainly NOT walking away, nor is anyone else going to get the rights to distribute Afrezza. A proven pharmaceutical giant who has the most effective insulin ever developed and KNOWING they have it does not just walk away after spending hundreds of $millions when they are barely out of the starting gate. They undoubtedly have planned this over a multi-year period, unlike retail investors who find a week to wait until the next Symphony script data an excruciating endeavour.
Just face it - the big money in MNKD is going to made over years, not a few more weeks. I'm outta here - too depressing to have to read stuff like this all the time
|
|
|
|
Post by dreamboatcruise on Dec 21, 2015 18:37:21 GMT -5
dudley... in general I agree with you... though I also have serious worries about MNKD's financing and what that will mean for investors.
|
|
|
|
Post by mssciguy on Dec 21, 2015 18:39:45 GMT -5
dudley Good for you. Maybe you could moonlight as Investor Relations for MNKD?
|
|
|
|
Post by sportsrancho on Dec 21, 2015 18:53:37 GMT -5
Good grief, this is complete nonsense. Sanofi has spent hundreds of millions of dollars to acquire exclusive rights to distribute Afrezza globally. Per Al Mann they were so eager to have it they started planning before the agreement was even officially signed. Now that real world experience has shown Afrezza to truly be in a class by itself and barely 10 months into what they undoubtedly understood would be a gradual uptake curve "investors" are so desperate they are coming up with nonsense like this? They just announced the discount card program would continue through 2016. They are in the middle of the pediatric trial. Results from that trial will HAVE to show clear superiority if they simply adjust the dosing period to be 15 minutes after the meal begins. SNY must understand that just as they must understand that a label change to clear superiority opens up the floodgates to demand from all sides - doctors and patients - as well as prime insurance coverage. A medication proven to lower HbA1c, hypos, and all the attendant impacts of diabetes such as neuropathy, blindness, etc. will be unmatched in the treatment universe. A label change allowing these statements both in advertising and sales literature - THAT is what they are "waiting for", almost guaranteed. The rollout and introductions will continue, but the massive blitz will not occur until a label change - it is only common sense and smart business. Sanofi is most certainly NOT walking away, nor is anyone else going to get the rights to distribute Afrezza. A proven pharmaceutical giant who has the most effective insulin ever developed and KNOWING they have it does not just walk away after spending hundreds of $millions when they are barely out of the starting gate. They undoubtedly have planned this over a multi-year period, unlike retail investors who find a week to wait until the next Symphony script data an excruciating endeavour. Just face it - the big money in MNKD is going to made over years, not a few more weeks. I'm outta here - too depressing to have to read stuff like this all the time Well said. Me too! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 21, 2015 19:32:43 GMT -5
dudley ... in general I agree with you... though I also have serious worries about MNKD's financing and what that will mean for investors. IMO that is the bet at this point. Do we have enough cash to out last the road blocks. I have no doubt Afrezza will succeed but MNKD's story will unfold over the next year. |
|
|
|
Post by bill on Dec 21, 2015 20:48:09 GMT -5
Kind of weird to realize that all it will take to turn around the MNKD story at this point is about $100m, now that we're pretty sure Afrezza is going to realize it's potential given time. That would have been a mere 10 million shares a few months ago. Now, the dilution path is almost out of reach. OTOH, we know that Al is very sensitive to cash flow and that Matt hasn't been behaving like a CFO in a cash crunch.
Maybe there really is a long-range plan that's going to work out just fine, but so far it's been a well-kept secret from investors. I wonder whether there's CTO language somewhere that frees up the cash MNKD received from SNY that's locked up on the balance sheet. We've all assumed it could only be used once Afrezza reaches some as yet undefined sales milestone, but perhaps there's also a time milestone. If so, a logical place for it would be the end of the 1st quarter in CY 2016.
Just another speculative guess on my part...
|
|
|
|
Post by EveningOfTheDay on Dec 21, 2015 21:10:13 GMT -5
Kind of weird to realize that all it will take to turn around the MNKD story at this point is about $100m, now that we're pretty sure Afrezza is going to realize it's potential given time. That would have been a mere 10 million shares a few months ago. Now, the dilution path is almost out of reach. OTOH, we know that Al is very sensitive to cash flow and that Matt hasn't been behaving like a CFO in a cash crunch. I certainly agree with the above stated. It seems it would have been a no brainer to do a small offering so as to insure there would be smooth financial sailing all the way till Afrezza was standing on its own. Why was not done that way is just one of the many unanswered questions we have. I guess it is easy to think that all this was done with sound reasons in mind. I wish I could be sure. |
|
|
|
Post by nadathing on Dec 21, 2015 21:10:54 GMT -5
Correct me if I'm wrong, but didn't Matt say they couldn't use the milestone money until they receive a profit from SNY's Afrezza sales? I believe he also said he did not expect to see profits until 2016 or 2017. With sales a slow as they are, it is looking like 2017 will be the earliest MNKD could become profitable from SNY sales. By then MNKD will need a cash infusion. Am I incorrect? Thanks.
|
|
|
|
Post by trenddiver on Dec 21, 2015 21:57:54 GMT -5
Correct me if I'm wrong, but didn't Matt say they couldn't use the milestone money until they receive a profit from SNY's Afrezza sales? I believe he also said he did not expect to see profits until 2016 or 2017. With sales a slow as they are, it is looking like 2017 will be the earliest MNKD could become profitable from SNY sales. By then MNKD will need a cash infusion. Am I incorrect? Thanks. You know "nadathing". |
|
